hotspot -WSS

hotspot

author：fashion 2025-09-27 23:00:43 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The UK government moves asylum

leisure time

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Diverse clinical trials: Why aren’t we there yet?

FDA approves updated Covid vaccines

Diverse clinical trials: Why aren’t we there yet?

In medicine, common shorthands can shortchange care

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

explore

hotspot

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At least 12 people were injured in a blast at a port in northwest Turkey

How to save PrEP access — and even expand it

Diverse clinical trials: Why aren’t we there yet?

Wildfire smoke exposes gaps in outdoor worker protections

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Novavax promises a turnaround & Lilly roils the obesity market

Democratic lawmaker calls for 'well

Novavax promises a turnaround & Lilly roils the obesity market

How to make the FDA’s new prescription one

hotspot

New weight loss drugs vying to be the next Wegovy or Mounjaro

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Moderna hits safety problems in bold bid to reinvent medicine

Long Covid needs a new name — and a new frame

Long Covid needs a new name — and a new frame

FDA approves updated Covid vaccines

focus

hotspot

leisure time

Wikipedia